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Purpose: Simple methods for the large-scale manufacture of ligand-
targeted liposomes will be needed if clinical trials are to proceed. We
tested a recently developed technology for inserting peptide ligands
into preformed Stealth liposomes. Antagonist G-targeted liposomes
(PLG) were prepared and loaded with doxorubicin and their cellular
association and cytotoxicity were evaluated using the human small
cell lung cancer H69 cell line.
Methods: The hexapeptide antagonist G was covalently coupled via a
thioether bond to the terminus of polyethylene glycol (PEG) in mi-
celles formed from maleimide-derivatized poly(ethylene glycol) (Mr
2000) distearoylphosphatidylethanolamine followed by transfer into
preformed liposomes during a one-step incubation. For cellular as-
sociation, we used radiolabeled liposomes. Cytotoxicity was evalu-
ated using the MTT in vitro proliferation assay.
Results: The postinsertion approach to the formation of peptide-
targeted liposomes led to the production of PLG bearing a maximum
of approximately 0.3 g antagonist G/mol phospholipid. These li-
posomes had increased cellular association to H69 cells relative to
nontargeted liposomes and, when loaded with doxorubicin, they re-
sulted in similar levels of cytotoxicity to those obtained by conven-
tional coupling techniques.
Conclusions: The postinsertion technique is a simple, effective means
for the production of biologically active peptide-targeted liposomes.
Key Words: antagonist G; polyethylene glycol; targeting; liposomes;
doxorubicin; small cell lung cancer.
INTRODUCTION
Liposomes sterically stabilized with polyethylene glycol
(Mr 2000) distearoylphosphatidylethanolamine conjugates
(mPEG-DSPE), known as Stealth® liposomes (SL), have long
circulation half-lives following intravenous injection (1). En-
trapment of anticancer drugs in SL results in increased tumor
accumulation and improved therapeutic efficacies, thus lead-
ing to the clinical approval of these novel liposome-based
formulations (2). The development of methods for coupling
cancer cell-specific ligands to a reactive terminus of the PEG
chain has created new opportunities for the use of liposomes
as homing devices for selective targeting of anticancer drugs
to diseased cells. This strategy has been shown to improve
the cytotoxicity and/or the therapeutic efficacy of encapsu-
lated drugs over nontargeted liposomes in animal models of
cancer (3).
We have recently shown that the growth factor antago-
nist H-Arg-D-Trp-NmePhe-D-Trp-Leu-Met-NH2, named an-
tagonist G (G), could be coupled to SL using conventional
coupling techniques (SLG). Antagonist G is a broad-spectrum
antagonist that competitively blocks the action of multiple
neuropeptides (e.g., vasopressin, gastrin-releasing peptide,
bradykinin) through its ability to bind to several receptors
(through the residues D-Trp-NmePhe-D-Trp-Leu) on the sur-
face of small cell lung cancer (SCLC) cells (4). SLG selec-
tively increased binding to, and internalization of liposomes
by, the human SCLC H69 cell line relative to SL (5). More-
over, SLG exhibit long circulating times in blood, which is
critical for in vivo tumor localization (6).
Preparation of SLG from liposomes that have coupling
lipids incorporated in the bilayer during their formation in-
volves several steps and a considerable length of time, and
leaves some reactive functional groups on the inner leaflet of
the lipid bilayer (7), which potentially can interfere with en-
capsulated materials. Simpler and more flexible methods for
the large-scale manufacture of ligand-targeted liposomes will
be needed if they are to proceed to clinical trials. Uster et al.
demonstrated that mPEG-DSPE could be transferred rapidly
from a micellar phase into the outer monolayer of preformed
PEG-free liposomes in a time- and temperature-dependent
manner, resulting in long-circulating liposomes (8). Maximum
PEG insertion from the micelles into the liposomes was
reached with 1 h incubations at 60°C. This postinsertion tech-
nique was extended to oligopeptide- (7), oligosaccharide- (7)
and to monoclonal whole antibody-PEG-DSPE conjugates
(9). In these latter two studies, transfer of ligands occurred
even when the preformed liposomes already contained a few
mol% of mPEG-DSPE. Ishida et al. showed that the postin-
sertion liposomes, made with monoclonal antibody anti-
CD19-PEG-DSPE conjugates, resulted in a threefold in-
crease in cellular association of the targeted liposomes to
CD19+ human B cell lymphoma cells compared with nontar-
geted liposomes. This result was similar to that obtained with
anti-CD19-targeted liposomes prepared by conventional cou-
pling techniques (3,9).
In this work we investigated whether use of the postin-
sertion technology could be extended to the preparation of
antagonist G-targeted liposomes (PLG). In addition, the cel-
lular association and cytotoxicity of doxorubicin-loaded lipo-
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ABBREVIATIONS: PEG, polyethylene glycol; DSPE, distear-
oylphosphatidylethanolamine; mPEG-DSPE, methyl-terminated
PEG (Mr 2000) linked via a carbamate bond to DSPE; Mal-PEG-
DSPE, maleimide-terminated PEG-DSPE; HSPC; hydrogenated soy
phosphatidylcholine; CHOL, cholesterol; SL, nontargeted sterically
stabilized liposomes; antagonist G, H-Arg-D-Trp-NmePhe-D-Trp-
Leu-Met-NH2; SLG, sterically stabilized (pegylated) liposomes con-
taining Mal-PEG-DSPE incorporated during liposome formation and
with antagonist G covalently coupled to the PEG terminus; antago-
nist G-PEG-DSPE, micellar Mal-PEG-DSPE with antagonist G co-
valently attached to the PEG terminus; PLG, SL in which antagonist
G-PEG-DSPE conjugates were inserted into the SL using the postin-
sertion approach; DXR, doxorubicin; SCLC, small cell lung cancer;
[3H] -CHE, [1,2(n)-3H] cholesterylhexadecyl ether; PL, phospho-
lipid; HEPES, N-(2-hydroxyethyl)piperazine-N’-(2-ethanesulfonic
acid); MES, 2-(N-morpholino)ethanesulfonic acid; IC50, inhibitory
concentration for 50% cell growth.
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somes prepared by this technique were evaluated in the
human SCLC H69 cell line.
MATERIALS AND METHODS
Materials
Antagonist G was synthesized by the Alberta Peptide
Institute (Edmonton, AB). Fully hydrogenated soy phospha-
tidylcholine (HSPC) and methoxy (polyethylene glycol) (Mr
2000) distearoylphosphatidylethanolamine (mPEG-DSPE)
were generous gifts of ALZA Corp. (Mountain View, Cali-
fornia). Cholesterol (CHOL) was purchased from Avanti Po-
lar Lipids (Alabaster, Alabama). Maleimide-derivatized
PEG2000-DSPE (Mal-PEG-DSPE) was custom synthesized
by Shearwater Polymers, Inc. (Huntsville, Alabama). Sigma-
cote, 2-iminothiolane, and 3-(4,5-dimethylthiazol-2-yl)2,5-
diphenyltetrazolium bromide (MTT) were purchased from
Sigma Chemical Co. (St. Louis, Missouri). [1,2(n)-3H] cho-
lesterylhexadecyl ether, 1.48-2.22 TBq/mmol ([3H] -CHE)
was purchased from Mandel Scientific (Guelph, Ontario). All
other chemicals were of analytical grade purity.
Cell Line
The human SCLC cell line NCI-H69 (ATCC HTB-119)
was purchased from the American Type Culture Collection.
It was cultured in RPMI 1640 media supplemented with 10%
(v/v) heat-inactivated fetal bovine serum, 100 U/ml penicillin,
and 100 g/ml streptomycin (GIBCO BRL, Grand Island,
New York) and maintained at 37°C in a humidified incubator
(90% humidity) in a 5% CO2 atmosphere. Cells were main-
tained within their exponential growth phase.
Preparation of Liposomes
Small unilamellar liposomes composed of HSPC:CHOL:
mPEG-DSPE at a 2:1:0.08 molar ratio, with or without 1
mol% of Mal-PEG-DSPE (total PEG of 5 mol% of phospho-
lipid), were prepared as previously described (10). Size was
determined by dynamic light scattering using a Brookhaven
BI-90 particle size analyzer V7.2 (Brookhaven Instruments,
Holtsville, New York). Liposomes containing doxorubicin,
DXR (Faulding, Vaudreuil Inc., PQ), were prepared in 250
mM ammonium sulfate, pH 5.5, and loaded via an ammonium
sulfate gradient, as previously described (11). The amount of
encapsulated DXR was determined from its absorbance at
492 nm following dissolution in methanol. Phospholipid con-
centration was determined from either the specific activity of
a [3H] -CHE lipid tracer or by the Bartlett colorimetric assay
(12).
Preparation of Antagonist G-Targeted Liposomes Either by
the Postinsertion Method or by Conventional Techniques
Dried lipid films containing Mal-PEG-DSPE were hy-
drated at a concentration of 0.333 mM in 25 mM HEPES, 25
mM MES, and 140 mM NaCl (pH 6.5) with gentle agitation
and heating at 65°C. Thiolated derivatives of antagonist G
were obtained by reacting the peptide with 2-iminothiolane at
a 1:4 molar ratio in 25 mM HEPES and 140 mM NaCl (pH
8.0) for 1 h at room temperature. At pH 8, 2-iminothiolane
reacts with primary amines in a ring-opening reaction that
regenerates the free sulfhydryl (13). The reaction is rapid and
efficient (13–15) and the rate of hydrolysis was found to be
negligible (13). Coupling of the thiolated antagonist G to the
PEG terminus of Mal-PEG-DSPE micelles took place during
an overnight incubation at room temperature, in siliconized-
coated glassware (Sigmacote) in an inert N2 atmosphere (16).
Free maleimide groups were quenched with an excess of
2-mercaptoethanol for 30 min at room temperature. Antago-
nist G-coupled PEG-DSPE micelles were then concentrated
in Centrisart I® tubes, size cut-off 5000 D (Sartorius AG,
Goettingen) and then dialyzed, for the purpose of DXR load-
ing, against a 250 mM ammonium sulfate solution overnight
at 4°C in Pierce Slide-A-Lyzer Dialysis Cassettes (Pierce,
Rockford, Illinois).
To prepare PLG, various ratios (1, 2, or 4 mol%) of
antagonist G-coupled PEG-DSPE micelles to liposomal phos-
pholipid (PL) were mixed with preformed liposomes for 1 h at
60°C. The resulting samples were then chromatographed on a
Sepharose CL-4B column (Pharmacia, Uppsala, Sweden) in
either 25 mM HEPES, 140 mM NaCl (pH 7.4), or 100 mM
sodium acetate, 70 mM NaCl (pH 5.5). The amount of an-
tagonist G on the liposomes was determined by fluorimetry at
ex  288 nm and em  330 nm.
Preparation of SLG by a conventional coupling tech-
nique was carried out under the same experimental condi-
tions described above. Instead of Mal-PEG-DSPE micelles,
Mal-PEG-DSPE-grafted liposomes were incubated with the
thiolated derivative of antagonist G overnight at room tem-
perature, in pH 6.5 HEPES buffer. After reaction with an
excess of 2-mercaptoethanol, the liposomes were chromato-
graphed on a Sepharose CL-4B column in pH 7.4 HEPES
buffer.
Cellular Association Studies
For cellular association studies, liposomes were labeled
with [3H] CHE. The term “cellular association” is used to
indicate a combination of binding to the cell surface plus
cellular internalization of the liposomes. SL, PLG, or SLG
were incubated with 1 × 106 H69 cells for 1 h at 37°C, as
previously described (3). The amount of [3H] CHE-
radiolabelled liposomes associated with cells was determined
from scintillation counting. Liposomal cellular association
was calculated from the specific activity of the lipid label [3H]
CHE in liposomes and was expressed as nmol of PL/106 cells.
In Vitro DXR Release Studies
All the DXR-containing liposomes (DXR-SL, DXR-
SLG or DXR-PLG) were freshly prepared and free DXR, if
any, was separated by elution over a Sephadex G-50 column
(Pharmacia). DXR release was determined from 0–48 h at
37°C in either pH 7.4 HEPES buffer, cell culture medium, or
25% human plasma in pH 7.4 HEPES buffer. The percentage
release of DXR was measured by fluorescence dequenching
measured on a CytoFluor 2350 fluorimeter (Millipore, Bed-
ford, MA) at ex  485 nm and em  590 nm. Complete
release (100% dequenching) of DXR was obtained by lysing
the liposomes with 25 l of 10% (v/v) Triton X-100 in distilled
water per milliliter of liposome suspension.
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Cytotoxicity Studies
The cytotoxicity of antagonist G-targeted liposomes con-
taining DXR, prepared either by the postinsertion or the Mal-
PEG-DSPE conventional coupling technique, was deter-
mined using the MTT cell proliferation assay. Briefly, H69
cells were seeded into 96-well plates at 8 × 104 cells/well and
incubated for 2, 24, or 48 h at 37°C in an atmosphere of 95%
humidity and 5% CO2. At the end of the incubation the cells
were gently washed twice with phosphate-buffered saline to
remove unbound liposomes. The cells were then maintained
in fresh medium at 37°C in an atmosphere of 95% humidity
and 5% CO2, for up to 5 days. Cell viability was then assessed
as previously described (17). The results were expressed in
terms of IC50 (M of DXR) determined from the dose-
response curves, and defined as the concentration of test
agents that produced a 50% reduction in cell viability com-
pared with drug-free control.
Statistical Analysis
The Student t-test was used to measure statistical signifi-
cance between pairs of samples. Data was considered signifi-
cant when P < 0.05.
RESULTS AND DISCUSSION
Antagonist G-targeted liposomes prepared by a conven-
tional Mal-PEG-DSPE coupling technique (5,6) averaged 1
g of antagonist G/mol of PL. The applicability of the
postinsertion technique for the preparation of antagonist G-
targeted liposomes was tested. The amount of antagonist G
coupled to micelles was approximately 0.6 mol antagonist
G/mol of PEG-DSPE, which corresponded to a coupling
efficiency of 60%. Preformed liposomes containing 4 mol%
(with respect to phospholipid) mPEG-DSPE were incubated
with 1, 2, or 4 mol% antagonist G-PEG-DSPE micelles, re-
sulting in 0.15 ± 0.02, 0.33 ± 0.08, and 0.34 ± 0.15 g, respec-
tively, of antagonist G/mol PL inserted into the final lipo-
somal preparations. Under these circumstances, 2–6% of an-
tagonist G-PEG-DSPE in the micellar conjugates mixture
was inserted into liposomes.
As expected, the cellular association of these samples
with the H69 cell line increased in proportion to the amount
of antagonist G conjugate incorporated into the preformed
liposomes (Fig. 1). At incorporation levels in the range of
0.15–0.34 g antagonist G/mol PL, the maximum cellular
association of PLG (1–1.8 nmol PL/106 cells) was intermedi-
ate between that seen for SLG preparations containing either
0.3 (0.8 nmol PL/106 cells) or 1 g (2.8 nmol PL/106 cells)
antagonist G/mol PL (Fig. 1). Hence, it appears that PLG
may have higher binding than SLG, at equivalent amounts of
antagonist G, although the hydrophobicity of the peptide,
combined with its small size, might lead to some nonspecific
association of unconjugated peptide in SLG that does not
contribute to binding. In contrast, when targeted liposomes
are made by the postinsertion method, the peptide is first
preconjugated to the large PEG-DSPE group and any uncon-
jugated peptide is removed by dialysis. This should lead to a
decrease in the nonspecific association of free peptide to the
liposomes during the insertion step, resulting in higher appar-
ent binding in the cellular assays.
It is important to point out that, although some mercap-
toethanol-reacted Mal-PEG-DSPE conjugates are inserted
into the outer monolayer of preformed liposomes, they are
biologically inert. The resulting product does not influence
the binding of liposomes at the cell level, which is evidenced
by the binding data presented in Fig. 1. Nontargeted lipo-
somes used in this experiment were originally made with the
same amount of Mal-PEG-DSPE as targeted liposomes, and
then quenched with an excess of 2-mercaptoethanol. The re-
sidual binding of these nontargeted liposomes (Fig. 1), is com-
parable to the cell binding obtained with nontargeted lipo-
somes prepared with mPEG-DSPE (i.e., without Mal-PEG-
DSPE, data not shown) and dramatically lower than that
obtained with antagonist G-targeted liposomes. Others have
confirmed the lack of cell binding of nontargeted liposomes
made from mercaptoethanol-reacted Mal-PEG-DSPE conju-
gates (18,19).
In an attempt to clarify whether the heating step of the
postinsertion methodology would affect the peptide binding,
SLG containing 1 g antagonist G/mol PL were concen-
trated and heated at 60°C for 1 h. Only a slight decrease in the
cellular association was observed relative to nonheated lipo-
somes containing the same amount of peptide (Fig. 1), sug-
gesting that antagonist G was fairly stable to heating.
The transfer of antagonist G conjugates to performed,
drug-loaded liposomes takes place above the phase transition
temperature for HSPC, at 60°C; therefore, the tendency for
the postinsertion method to cause release of the encapsulated
DXR was elevated. Interestingly, a 1 h incubation at 60°C of
DXR-loaded liposomes containing 4 mol% of mPEG-DSPE
with antagonist G-PEG-DSPE micelles contributing a further
2 mol% of PEG, resulted in 87% of DXR leakage. Even
when the content of mPEG-DSPE in preformed liposomes
was increased to 9 mol%, 60% of drug leakage was observed
at 1 h. Ishida et al. observed that little DXR leakage occurred
when DXR-loaded liposomes (similar to those in this study)
were heated at 60°C for 6 h, either alone or in the presence of
IgG-PEG-DSPE micelles (9). These data suggest that hydro-
Fig. 1. Cellular association of [3H] CHE-labeled liposomes with H69
cells. Liposomes were incubated with 1 × 106 H69 cells for 1 h at 37°C
at 0.1–0.8 mM PL/well. Nontargeted liposomes (  ); targeted li-
posomes made by the postinsertion method containing 0.15 ( ),
0.33 (  ) or 0.34 (  ) g antagonist G/mol PL. Targeted lipo-
somes made by the Mal-PEG-DSPE method containing 0.3
(  ) or 1 g (—— , ——) antagonist G/mol PL, where one of
the samples (——) was concentrated and heated for 1 h at 60°C.
Data was expressed as nmol of PL/106 cells. Each point is the mean
of three samples, ± SD, from one representative experiment.
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phobic antagonist G may cause some membrane perturba-
tion, which could be either permanent or transient. Subse-
quently, experiments with DXR-loaded liposomes were per-
formed by loading DXR after insertion of the antagonist
G-PEG-DSPE conjugates. In these preparations, DXR re-
lease was evaluated in different media (Fig. 2). After 36 h at
37°C, regardless of the incubation media or the coupling
method (SLG or PLG), the drug release was approximately
the same as that observed for nontargeted liposomes. Thus,
these data suggest that the membrane perturbation induced
by insertion of antagonist G-PEG-DSPE conjugates may
have been due to direct interaction of the hydrophobic pep-
tide with the liposomal membranes during the transfer pro-
cess. With completion of the insertion step, the peptide at the
PEG terminus may be oriented away from the membrane
surface, preventing further membrane disruption.
The size of the liposomes is a critical parameter for their
in vivo application. Ideally, the average diameter of liposomes
should be approximately 100 nm to minimize hepatosplenic
uptake (20) and to ensure extravasation into diseased tissues
such as solid tumors (21). The mean liposome diameter be-
fore and after insertion of antagonist G-PEG-DSPE was mea-
sured to determine if PLG met these requirements. For sev-
eral experimental replicates the mean liposome diameter was
only slightly increased (3–4 nm) by the insertion of antagonist
G conjugates. Final diameters ranged from 94–99 nm with a
polydispersion index of 0.060–0.100.
PLG exhibit apparent higher cellular association than
SLG at similar peptide concentrations, so the cytotoxicity of
DXR-loaded SLG vs. PLG was compared in the H69 cell line
(Fig. 3). For liposomes containing similar amounts of peptide
(0.3 g/mol PL), DXR-PLG were 18-fold more cytotoxic
than DXR-SLG (P < 0.001) for a 2 h incubation. The mag-
nitude of the difference decreased at longer incubation times,
but remained statistically significant. There was a sixfold ad-
vantage for DXR-PLG at 24 h (P < 0.001) and twofold ad-
vantage at 48 h (P < 0.01). It is interesting to mention that
although the cellular association for PLG coupled to 0.33 g
peptide/mol PL was lower than that observed for SLG
coupled to 1 g peptide/mol PL, both formulations medi-
ated similar levels of cytotoxicity, according to previous data
(5).
Overall, these data support the hypothesis that antago-
nist G on postinsertion targeted liposomes was either more
available to interact with the receptors on the surface of the
target cells and/or more efficiently internalized. For example,
in SLG some of the peptide added during the coupling pro-
cedure may insert into the liposomal membrane through hy-
drophobic interactions and not couple to the PEG terminus.
Control experiments in which SLG were incubated with lipo-
somes containing Mal-PEG-DSPE under conditions in which
no coupling could take place showed that approximately 16%
of the added peptide was associated with the SLG in a non-
specific manner. The fraction of the peptide that was not
coupled to the PEG terminus in SLG would probably not
participate in the binding process to cells. Cellular association
represents binding + internalization, so the higher cellular
association levels of PLG at similar amounts of coupled pep-
tide may also be due to more efficient internalization of the
PLG, leading to higher levels of DXR delivered intracellu-
larly and higher levels of cytotoxicity.
In summary, we have shown that antagonist G could be
coupled to Mal-PEG-DSPE micelles and the resulting pep-
tide-PEG-DSPE conjugates could be transferred into pre-
formed liposomes in a one-step incubation without signifi-
cantly affecting liposome diameter. At similar levels of incor-
porated peptide, PLG had higher levels of cellular association
than SLG, which resulted in greater cytotoxicity. Our data
suggests that the postinsertion method of generating ligand-
targeted liposomes may be an effective means of limiting non-
specific absorption of ligand to liposomes when ligands with
limited solubility, such as this hydrophobic peptide, are in-
volved. The extension of the postinsertion technique to in-
clude peptide-PEG-DSPE conjugates confirms the flexibility
of this approach to the preparation of targeted liposomes.
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Fig. 2. Release of encapsulated self-quenched DXR from liposomes
following their incubation in various media for 36 h at 37°C. DXR
release from DXR-SL (), DXR-PLG ( ), and DXR-SLG () was
determined either in pH 7.4 HEPES buffer, cell culture medium, or
in 25% human plasma in pH 7.4 HEPES buffer. Results were ex-
pressed as a percentage of total trapped DXR released. Each point is
the mean of three to six samples, ± SD, from one representative
experiment.
Fig. 3. Cytotoxicity of doxorubicin-loaded PLG vs. SLG against H69
cells. H69 cells (8 × 104/well) were incubated with either DXR-PLG
( ) or DXR-SLG () containing 0.3 g antagonist G/mol PL. In-
cubations were carried out for 2, 24, and 48 h. Data is expressed as
IC50 in M of DXR (mean ± SD, of three to four independent
experiments).
Moreira, Ishida, Gaspar, and Allen268
REFERENCES
1. D. Papahadjopoulos, T. M. Allen, A. Gabizon, E. Mayhew,
K. Matthay, S. K. Huang, K. D. Lee, M. C. Woodle, D. D. Lasic,
C. Redemann, and F. J. Martin. Sterically stabilized liposomes:
improvements in pharmacokinetics and antitumor therapeutic
efficacy. Proc. Natl. Acad. Sci. USA 88:11460–11464 (1991).
2. D. W. Northfelt, F. J. Martin, P. Working, P. A. Volberding,
J. Russell, M. Newman, M. A. Amantea, and L. D. Kaplan.
Doxorubicin encapsulated in liposomes containing surface-bound
polyethylene glycol: pharmacokinetics, tumor localization, and
safety in patients with AIDS-related Kaposi’s sarcoma. J. Clin.
Pharmacol. 36:55–63 (1996).
3. D. E. Lopes de Menezes, L. M. Pilarski, and T. M. Allen. In vitro
and in vivo targeting of immunoliposomal doxorubicin to human
B-cell lymphoma. Cancer Res. 58:3320–3330 (1998).
4. P. J. Woll and E. Rozengurt. A neuropeptide antagonist that
inhibits the growth of small cell lung cancer in vitro. Cancer Res.
50:3968–3973 (1990).
5. J. N. Moreira, C. B. Hansen, R. Gaspar, and T. M. Allen (eds.).
Controlled Release Society, Inc. In vitro targeting of poly(ethyl-
ene glycol)-grafted liposomes by hexapeptide to a classical small
cell lung cancer cell line. In Proceedings of the 26th International
Symposium on Controlled Release of Bioactive Materials, June
20–25, Boston, Massachusetts, 1999, p. 6215.
6. J. N. Moreira, C. B. Hansen, R. Gaspar, and T. M. Allen (eds.).
Organizing Committee of the IV Spanish-Portuguese Conference
on Controlled Drug Delivery. Pharmacokinetic properties and
biodistribution of hexapeptide-targeted Stealth® liposomes. In
Proc. IV Spanish-Portuguese Conference on Controlled Drug
Delivery, September 17-20, Vitoria, Spain, 2000, pp. 169–170.
7. S. Zalipsky, N. Mullah, J. A. Harding, J. Gittelman, L. Guo, and
S. A. DeFrees. Poly(ethylene glycol)-grafted liposomes with oli-
gopeptide or oligosaccharide ligands appended to the termini of
the polymer chains. Bioconjug. Chem. 8:111–118 (1997).
8. P. S. Uster, T. M. Allen, B. E. Daniel, C. J. Mendez, M. S. New-
man, and G. Z. Zhu. Insertion of poly(ethylene glycol) deriva-
tized phospholipid into pre-formed liposomes results in pro-
longed in vivo circulation time. FEBS Lett. 386:243–246 (1996).
9. T. Ishida, D. L. Iden, and T. M. Allen. A combinatorial approach
to producing sterically stabilized (Stealth) immunoliposomal
drugs. FEBS Lett. 460:129–133 (1999).
10. F. Olson, C. A. Hunt, F. C. Szoka, W. J. Vail, and D. Papahad-
jopoulos. Preparation of liposomes of defined size distribution by
extrusion through polycarbonate membranes. Biochim. Biophys.
Acta 557:9–23 (1979).
11. E. M. Bolotin, R. Cohen, L. K. Bar, N. Emanuel, S. Ninio,
D. D. Lasic, and Y. Barenholz. Ammonium sulphate gradients
for efficient and stable remote loading of amphipatic weak bases
into liposomes and ligandoliposomes. J. Liposome Res. 4:455–479
(1994).
12. G. R. Bartlett. Phosphorus assay in column chromatography.
J. Biol. Chem. 234:466–468 (1959).
13. G. T. Hermanson. Introduction of sulfhydryl residues (thiola-
tion): modification of amines with 2-iminothiolane (Traut’s re-
agent). In G. T. Hermanson, (ed.), Bioconjugate Techniques,
Academic Press, San Diego, California, 1996, pp. 56–60.
14. R. Jue, J. M. Lambert, L. R. Pierce, and R. R. Traut. Addition of
sulfhydryl groups to Escherichia coli ribosomes by protein modi-
fication with 2-iminothiolane (methyl 4-mercaptobutyrimidate).
Biochemistry 17:5399–5406 (1978).
15. G. E. Means and R. E. Feeney. Chemical modifications of pro-
teins: history and applications. Bioconjug. Chem. 1:2–12 (1990).
16. F. J. Martin and D. Papahadjopoulos. Irreversible coupling of
immunoglobulin fragments to preformed vesicles. An improved
method for liposome targeting. J. Biol. Chem. 257:286–288
(1982).
17. D. E. Lopes de Menezes, M. J. Kirchmeier, J. F. Gagne, L. M.
Pilarski, and T. M. Allen. Cellular trafficking and cytotoxicity of
anti-CD19-targeted liposomal doxorubicin in B lymphoma cells.
J. Liposome Res. 9:199–228 (1999).
18. D. Kirpotin, J. W. Park, K. Hong, S. Zalipsky, W. L. Li, P. Carter,
C. C. Benz, and D. Papahadjopoulos. Sterically stabilized anti-
HER2 immunoliposomes: design and targeting to human breast
cancer cells in vitro. Biochemistry 36:66–75 (1997).
19. D. L. Iden and T. M. Allen. In vitro and in vivo comparison of
immunoliposomes made by conventional coupling techniques
with those made by a new post-insertion approach. Biochim. Bio-
phys. Acta 1513:207–216 (2001).
20. D. C. Litzinger, A. M. Buiting, N. van Rooijen, and L. Huang.
Effect of liposome size on the circulation time and intraorgan
distribution of amphipathic poly(ethylene glycol)-containing li-
posomes. Biochim. Biophys. Acta 1190:99–107 (1994).
21. O. Ishida, K. Maruyama, K. Sasaki, and M. Iwatsuru. Size-
dependent extravasation and interstitial localization of polyeth-
yleneglycol liposomes in solid tumor-bearing mice. Int. J. Pharm.
190:49–56 (1999).
Insertion of Peptide Ligands into Stealth Liposomes 269
